New cholesterol pill reduces dangerous LDL by nearly 60%.

In a large international trial, researchers tested a new compound designed to act precisely on a key switch protein in fat metabolism. Rather than requiring injections, it is taken as a simple once-daily tablet. The early numbers look striking - but what might they actually mean for people at high risk of a heart attack or stroke?

Why LDL cholesterol is so dangerous

LDL cholesterol is widely seen as the main driver of atherosclerosis (hardening and narrowing of the arteries). When LDL builds up in blood vessel walls, plaques gradually form. Over time, these plaques narrow the arteries, restrict blood flow and can rupture suddenly - which is when a heart attack or stroke can occur.

For that reason, clinical guidelines have set clear targets for years: anyone who already has cardiovascular disease, or who carries a particularly high risk, is advised to lower LDL substantially - often to 70 or even 55 milligrams per decilitre of blood.

In real-world care, that does not work out for everyone. Many patients still fail to reach their targets despite intensive treatment. The most common tool is statins: they slow cholesterol production in the liver and increase the removal of LDL from the bloodstream. Statins are well studied and can reduce LDL noticeably, but for high-risk patients the effect is often not enough.

"If you have a high heart attack risk, you don’t need ‘a bit less’ - you need a lot less LDL in your blood."

What sits behind the new cholesterol tablet

This is exactly where a newer strategy comes in, aimed at the PCSK9 protein family. These proteins influence how many LDL receptors sit on the surface of liver cells. Fewer receptors means the blood is less effectively “cleared” of LDL.

The new agent, called Enlicitid, is intended to block PCSK9. When PCSK9 is inhibited, more LDL receptors remain active, the liver captures more LDL particles from the bloodstream, and LDL levels fall.

PCSK9 inhibitors are not entirely new: antibody therapies already exist and are administered under the skin via injection or pen. On average, they reduce LDL by around 60%. Although effective, these injections are used relatively infrequently in day-to-day practice. Common reasons include:

• the practical burden of regular injections,
• many patients’ reluctance to self-inject,
• high costs and administrative hurdles when prescribing.

The key idea with Enlicitid is convenience: it is a tablet taken once daily. That could lower the barrier to use - for both clinicians and patients.

The phase 3 trial: nearly 3,000 high-risk participants

In the newly published phase 3 trial, 2,909 people were followed up. The average age was 63, and around 40% were women. Every participant either already had cardiovascular disease or was considered high risk for other reasons.

At baseline, the mean LDL was 96.1 milligrams per decilitre - clearly above the recommended targets for this group. Many participants were already taking statins, but were still not adequately controlled.

Participants received either 20 milligrams of Enlicitid once daily or a placebo. After 24 weeks, the difference between the groups was clear.

"With 20 milligrams daily, LDL fell by an average of 57.1% - while under placebo it barely changed."

The tablet did not only affect LDL. Other blood fats and particles linked to cardiovascular harm also decreased, including:

• cholesterol not bound to HDL (“non-HDL cholesterol”),
• apolipoprotein B, a carrier protein for atherogenic particles,
• lipoprotein(a), another risk factor that is often genetically determined.

In the reported data, the effects persisted through week 52. Tolerability appeared similar in the Enlicitid and placebo groups, and no major safety concerns stood out in this analysis.

What these figures could mean for patients

For people who remain well above their LDL target despite statins, adding a tablet that lowers LDL by almost 60% could feel like a potential game-changer. The reasoning is straightforward: every percentage point less LDL over years reduces the cumulative burden on the arteries.

Achieving such a large reduction with a tablet could bring several practical benefits:

• More intensive treatment without injections: clinicians could strengthen therapy substantially without moving to injectable options.
• Better adherence: many patients find it easier to take a pill than to inject themselves regularly.
• Simpler combination therapy: Enlicitid could be added alongside statins and other cholesterol-lowering medicines.

One crucial question remains unanswered, however: does this impressive reduction in laboratory values translate into fewer heart attacks and strokes in everyday life? That is exactly what an ongoing outcomes component is intended to clarify by tracking clinical events over a longer period.

New building blocks for cardiovascular prevention

In preventing cardiovascular disease, it is not only today’s LDL level that matters, but the lifetime LDL burden built up over years and decades. Spending a long time with elevated LDL leads to more accumulated damage in the vessels.

A potent tablet that dramatically lowers LDL could materially reduce that overall exposure. Especially for people who have already had a heart attack, or who have multiple risk factors, it could widen the treatment options available to clinicians.

Modern prevention, however, still relies on several pillars:

• lowering LDL with medicines (statins and, where appropriate, add-on therapies such as Enlicitid),
• controlling blood pressure,
• not smoking,
• physical activity and weight management,
• an adjusted diet low in highly processed fats and sugar.

No medicine replaces these fundamentals; it can only complement them. At the same time, people who already maintain strong lifestyle habits may gain particularly from additional drug options because their overall risk can be reduced further.

How PCSK9 inhibitors work inside the body

To place the new tablet in context, it helps to briefly outline the mechanism. The liver has many docking sites that pull LDL out of the bloodstream. PCSK9 marks some of these receptors for breakdown. When that protein is inhibited, more receptors stay functional.

So PCSK9 inhibitors do not primarily increase the excretion of cholesterol itself; instead, they increase the liver’s capacity to clear LDL from the blood. With fewer LDL particles circulating, there are fewer that can attach to vessel walls.

Enlicitid applies this principle in tablet form. More detail on the precise drug class and long-term safety still needs to be gathered. Researchers are also focusing on potential interactions with other medicines, such as anticoagulants (blood thinners) or certain blood pressure treatments.

Risks, open questions and practical examples

As with any new therapy, patients tend to ask the same core questions: what side effects might occur, who should take the tablet, and when is it genuinely worth using?

So far, available data suggest a side-effect profile comparable to placebo. Well-known problems in cholesterol treatment - for example muscle symptoms - are largely associated with statins rather than PCSK9 inhibitors. Whether very long treatment durations lead to additional effects will only be clarified by studies running over many years.

Typical candidates for such a tablet could include, for example:

• a 58-year-old man who has already had a heart attack and remains clearly above target despite a high-dose statin,
• a 65-year-old woman with diabetes, reduced kidney function and genetically driven high cholesterol,
• people with extremely high LDL from a young age, where genetic factors play a major role.

For these groups, an additional tablet option could be the difference between “better than before” and “truly within target range”. Whether the cost ultimately ends up similar to today’s injectable PCSK9 treatments - or lower - will depend on price negotiations and regulatory strategy, and remains unresolved at present.

It will likely still take a few years before the tablet becomes routine in everyday care. First, outcomes data on preventing heart attacks and strokes need to be convincing; then come regulatory approvals and reimbursement decisions. Even so, for people at high risk the signal is already clear: the range of effective tools against dangerously high LDL is likely to expand noticeably in the near future.